Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$70.6MBeat by $54.8M
EPS-$0.34Beat by $0.48
Revenue estimate$15.8M
EPS estimate-$0.82

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$4.0M
EPS estimate-$0.99

Financials

Q3 2025

Income statement

See full
Revenue$70.6M+81,958%
Operating income-$40.0M+52.1%
Net income-$34.6M+54.9%

Balance sheet

See full
Cash & equivalents$169.6M-15.3%
Total debt$23.8M+2.2%
Total equity$503.0M-28.9%
Total assets$577.1M-25.2%

Cash flow

See full
Operating cash flow-$84.6M-25.0%
CapEx$127.0K-56.7%
Free cash flow-$84.7M-24.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.76B+1.4%
Enterprise value$1.62B+3.6%
P/S24.9×-5,727×

Profitability

See full
Operating margin-463.5%-231pp
Net margin-426.6%-213pp
FCF margin-461%-230pp

Returns & leverage

See full
Return on equity-49.9%-1.8pp
Debt / equity0×0.0×
Current ratio11.3×-7.3×

FAQ

When did Viridian Therapeutics, Inc. report Q3 2025 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Viridian Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $70.6M and eps of $-0.34 for Q3 2025.
Did Viridian Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $15.8M by $54.8M. EPS beat the consensus estimate of $-0.82 by $0.48.
How did Viridian Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 81958.1% from $86.0K a year earlier and eps grew 70.4% from $-1.15.
Where can I find Viridian Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-265711) and the 10-Q periodic report (0001590750-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.